Compare Dow Jones Industrial Average ETF (DIA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Novo Nordisk A/S — how do they compare? Dow Jones Industrial Average ETF trades at $516.39 (market cap $45.20B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Dow Jones Industrial Average ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Novo Nordisk A/S for 116 Days on average.
| DIA | NVO | |
|---|---|---|
Market Cap | $45.20B | $165.31B |
Volume | 4,095,368 | 11,432,838 |
52-Week High | $542.79 | $63.98 |
52-Week Low | $451.37 | $35.29 |
Typical Hold Time | 104 Days | 116 Days |
Sector | — | Health |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $516.07, up 0.99% with bearish technical signals from moving averages. The ETF maintains dividend distributions with three recent payouts scheduled through October 2026. Market sentiment reflects broader volatility concerns amid economic uncertainty and Fed policy speculation.
The ETF's outlook remains tied to Dow component performance, with technical resistance at $516 limiting near-term upside. Dividend consistency provides income stability, though bearish momentum and market-wide pressures pose headwinds for large-cap value exposure.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
